On March 7, 2016, International Stem Cell Corporation
(OTCQB: ISCO) announced that the Melbourne Health Human Research Ethics
Committee (HREC) had approved its application to initiate phase I clinical
trials of ISC-hpNSC® (human parthenogenetic neural stem cells) for the
treatment of moderate to severe Parkinson’s disease. With that approval, ISCO
has begun enrolling patients for those phase I clinical trials in what marks a
major milestone for the company.
International Stem Cell Corporation is researching new ways
to increase the quality and length of human life spans through regenerative
technologies that augment or replace organ transplants, developments made
possible by the discovery of the structure of deoxyribonucleic acid (DNA) in
1953 by American biologist James Watson and English physicist Francis Crick.
DNA was first identified (http://dtn.fm/Elyc9) by the Swiss physiological
chemist Friedrich Miescher in 1869. The knowledge that the DNA molecule exists
in the form of a three-dimensional double helix has been hailed as one of the
‘two radical developments over the past sixty years’ in medicine in What
Happened to the Future (http://dtn.fm/FqxA9), a lament on the slow pace of
present technological development.
The What Happened to the Future jeremiad penned by the
venture capitalist Bruce Gibney while at Founders Fund tells how it used to be.
‘Less than twenty-five years after Watson and Crick published the structure of
DNA, venture capitalist Robert Swanson and biochemist Herbert Boyer founded
Genentech, now a subsidiary of Roche (OTCQX: RHHBY), which went on to
synthesize insulin far faster and more cheaply than almost anyone believed
possible. And in a great revolution in the FDA approval process in the 1980s
following pressure from the AIDS lobby, the agency acted almost nimbly to
approve a huge number of important new drugs for many maladies.’
However, since then the drug development process has become
notoriously tortuous and costly. It starts with drug discovery, when new
insights into how a disease progresses allow researchers to design a product to
stop or reverse its effects. Alternatively, a number of molecular compounds may
be tested to determine what effect, if any, they may have against a range of
medical conditions. Sometimes, good fortune may come of the ubiquitous side
effects. A drug prescribed for one condition may be found to have benefits in
other areas. And then, of course, there are the new technologies like ISCO’s
human parthenogenetic stem cell (hpSC) technology.
After a particular compound has been identified, it must be
subjected to pre-clinical trials. Pre-clinical trials, or, as they are
sometimes called, non-clinical testing, may be pharmacodynamic (examining what
the drug does to the body); pharmacokinetic (examining what the body does to
the drug); may examine how the compound is absorbed, distributed, metabolized
and excreted by the body; or may attempt to determine its toxicity. In some
instances, animals may be employed in pre-clinical trials.
It is only after greater knowledge of the compound has been
obtained through pre-clinical testing that it will be administered to humans in
clinical trials. Clinical trials typically may have four phases, each of which
is designed to answer a research question. In phase I, researchers test a new
drug or treatment in a small group of people for the first time to evaluate its
safety, determine a safe dosage range, and identify side effects. This is the
point that ISCO has reached with its human parthenogenetic stem cell ISC-hpNSC®
technology.
In phase II clinical trials, the compound is given to a
larger group of people to see if it is effective and to further evaluate its
safety. In phase III studies, the drug is administered to an even larger group
of people to confirm its effectiveness, monitor side effects, compare it to
commonly used treatments, and collect information that will allow the drug or
treatment to be used safely. Phase IV testing is conducted after the drug has
been marketed to gather information on the drug’s effect in various populations
and any side effects associated with long-term use.
Before a drug can be marketed, it will be reviewed by the
FDA when the sponsoring company submits a new drug application (NDA). And for
many years to come, the FDA will continue its post-market safety monitoring.
It’s quite a journey for a drug discovery company to take, but mindful of
Gibney’s complaint, International Stem Cell Corporation is forging ahead with
the phase I trials, which will be performed at the Royal Melbourne Hospital in
Australia.
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment